Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398170 | 1.00 | GSR (0.50) | GSRTRPA1BLMKDM4EALDH1A1 | |
| SCHEMBL14935978 | 1.00 | GSR (0.50) | GSRTRPA1BLMKDM4EALDH1A1 | |
| SCHEMBL4426985 | 0.87 | GSR (0.57) | GSRTRPA1BLMKDM4ETAAR1 | |
| SCHEMBL8602813 | 0.86 | GSR (0.49) | GSRTRPA1BLMKDM4EALDH1A1 | |
| SCHEMBL27558997 | 0.84 | TRPA1 (0.50) | GSRTRPA1KDM4EALDH1A1TAAR1 | |
| SCHEMBL22861354 | 0.83 | TRPA1 (0.39) | GSRTRPA1TAAR1 | |
| SCHEMBL14945485 | 0.82 | TRPA1 (0.47) | GSRTRPA1BLMKDM4EALDH1A1 | |
| SCHEMBL13843585 | 0.82 | TRPA1 (0.47) | GSRTRPA1BLMKDM4EALDH1A1 | |
| SCHEMBL20220566 | 0.82 | CHRNA7 (0.39) | GSRKDM4EALDH1A1 | |
| SCHEMBL7417686 | 0.81 | GSR (0.49) | GSRTRPA1BLMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | EVOTEC (FRANCE) SAS (FR) | 2023-01-19 | — | — | US | disclosed |
| CN-109970760-B | ACC inhibitors and uses thereof | 吉利德阿波罗公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3628320-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2021195599-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-11021492-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC | 2015-07-23 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2776038-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | GSR 2701/4885TRPA1 4691/4885BLM 4009/4885 |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | GSR 2701/4885TRPA1 4691/4885BLM 4009/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | GSR 2701/4885TRPA1 4691/4885BLM 4009/4885 |
| US-20150203510-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | GSR 1846/4885TRPA1 4839/4885BLM 3627/4885 |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | GSR 2701/4885TRPA1 4691/4885BLM 4009/4885 |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | GSR 2701/4885TRPA1 4691/4885BLM 4009/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | GSR 1846/4885TRPA1 4839/4885BLM 3627/4885 |
| US-11021492-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | GSR 2701/4885TRPA1 4691/4885BLM 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.